This trial will compare the amount of bone pain experienced by breast cancer patients who receive a single dose of Pegfilgrastim to those who receive 5 doses of daily filgrastim while undergoing neoadjuvant/adjuvant chemotherapy.
- Breast Cancer
1 Primary · 10 Secondary · Reporting Duration: 5 days after first G-CSF injection
Awards & Highlights
2 Treatment Groups
1 of 2
5 Days of Filgrastim
1 of 2
233 Total Participants · 2 Treatment Groups
Primary Treatment: Pegfilgrastim · No Placebo Group · Phase 4
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many participants are the maximum capacity for this experiment?
"Affirmative, the information hosted on clinicaltrials.gov shows that this medical study is still recruiting participants. The trial was first posted on June 9th 2021 and most recently edited November 5th 2022; 232 people are required from two different sites." - Anonymous Online Contributor
Are volunteers still being recruited for this investigation?
"Clinicaltrials.gov affirms that recruitment is in progress for this medical experiment, which was posted on June 9th 2021 and adjusted as recently as November 5th 2022." - Anonymous Online Contributor
What potential hazards have been associated with the use of Pegfilgrastim?
"There is already regulatory approval for Pegfilgrastim, which has been granted a safety score of 3." - Anonymous Online Contributor
What conditions do physicians typically prescribe Pegfilgrastim to treat?
"Pegfilgrastim is most commonly administered to alleviate severe congenital neutropenia, though it may also provide relief from acute leukemia and other malignant neoplasms." - Anonymous Online Contributor
To what extent has Pegfilgrastim been utilized in other clinical experiments?
"Currently, 172 trials are underway that involve Pegfilgrastim. 40 of these studies have advanced to the third and final phase while 5807 sites across the world are running tests regarding this drug's efficacy. The majority of clinical research is taking place in Saint Louis, Missouri." - Anonymous Online Contributor